Salute e Benessere
TAGRISSO Sets the Stage for Market Leadership in Oncology with Strong Growth Prospects | DelveInsight
TAGRISSO is a prescription medication for adults with non-small cell lung cancer (NSCLC) that carries specific EGFR gene mutations. It is used to help prevent cancer recurrence after surgical tumor removal, as a first-line treatment for metastatic NSCLC, or for patients whose cancer has spread and no longer responds to prior EGFR TKI therapy.
As a kinase inhibitor, TAGRISSO irreversibly targets specific mutant forms of EGFR (T790M, L858R, and exon 19 deletions) with significantly higher selectivity than the wild-type EGFR. After oral administration, two active metabolites (AZ7550 and AZ5104) circulate at around 10% of the parent drug and exhibit similar inhibitory effects as osimertinib. In vitro studies also show that osimertinib inhibits HER2, HER3, HER4, ACK1, and BLK at clinically relevant levels.
The recommended TAGRISSO dosage is 80 mg once daily, taken with or without food, and continued until disease progression or unacceptable toxicity occurs.
JP: 2016
Learn more about TAGRISSO projected market size for EGFR mNSCLC @
EGFR is a protein that plays a crucial role in cell growth. When mutations occur in the EGFR gene, they can lead to excessive cell growth, potentially causing cancer. These mutations can take various forms, including deletions, insertions, and point mutations. Among the most common EGFR mutations detected in test results are the EGFR exon 19 deletion and the EGFR L858R point mutation.
In non-small cell lung cancer, targeted therapies primarily focus on EGFR-sensitizing mutations and EGFR exon 20 insertions. The most frequently observed EGFR mutations include exon 19 deletions and exon 21 L858R mutations. To address these, the FDA has approved several tyrosine kinase inhibitors (TKIs).
In 2023, the EGFR-mutated NSCLC market across the 7MM was valued at approximately . The NSCLC treatment landscape is becoming increasingly biomarker-driven, with EGFR emerging as one of the most lucrative targets. remains the leading therapy in this segment, maintaining a strong market presence. However, resistance to EGFR TKIs, particularly after TAGRISSO treatment, is a growing challenge. Developing treatments for patients who experience resistance remains one of the most pressing unmet needs in this space.
Discover more about the EGFR mNSCLC market in detail @
The promising candidates in EGFR NSCLC pipeline include (Daiichi Sankyo/AstraZeneca), (Cullinan Oncology/Taiho Pharma), (Jiangsu Hansoh Pharmaceutical), (AstraZeneca/Hutchison MediPharma), (Akeso Biopharma/Summit Therapeutics), (ArriVent BioPharma), (Dizal Pharmaceutical), (Biotheus/BioNTech), (Jazz Pharmaceuticals), (Taiho Oncology), (RedCloud Bio), (J INTS BIO), (Forward Pharma), (Pfizer), (Merus), (Genprex), (Promontory Therapeutics), (Hummingbird Bioscience), (Avistone Biotechnology), (Kairos Pharma), and others.
To know more about the number of competing drugs in development, visit @
Discover how TAGRISSO is shaping the EGFR NSCLC treatment landscape @
TAGRISSO, developed by AstraZeneca, is a third-generation EGFR TKI that has become a key player in the treatment of . Since its approval, TAGRISSO has gained significant traction due to its , particularly in patients with the T790M resistance mutation. The drug's ability to penetrate the has further strengthened its market positioning, leading to widespread adoption among oncologists.
A major driver of TAGRISSO's market dynamics is its dominance as the preferred
. This shift from earlier-generation TKIs has been supported by clinical data demonstrating
. The expansion of TAGRISSO's indications, including its approval in the
, has further broadened its market reach. Additionally, AstraZeneca has aggressively pursued
, ensuring market access across multiple geographies, particularly in high-prevalence regions such as
East Asia , where EGFR mutations are more common.
However, TAGRISSO faces growing challenges, including the such as MET amplification and C797S mutations, which limit long-term efficacy. To counteract this, AstraZeneca is exploring combination strategies with MET inhibitors and other targeted therapies. Furthermore, , such as those under development by companies like Takeda and Johnson & Johnson, poses a potential threat. , particularly in cost-sensitive markets, also impact its commercial strategy, necessitating a balance between pricing optimization and maintaining accessibility.
Despite these challenges, TAGRISSO remains a blockbuster drug with robust revenue growth, driven by . Ongoing clinical trials evaluating its use in could further extend its market leadership. With its strong foothold in the EGFR-mutated NSCLC landscape, TAGRISSO is expected to remain a of AstraZeneca's oncology portfolio in the foreseeable future.
Dive deeper to get more insight into TAGRISSO's strengths & weaknesses relative to competitors @
report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key EGFR NSCLC companies, including among others.
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key EGFR non-small cell lung cancer companies, including among others.
report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NSCLC companies including among others.
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key non-small cell lung cancer companies, including among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
Shruti Thakur
info@delveinsight.com
+14699457679
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/tagrisso-sets-the-stage-for-market-leadership-in-oncology-with-strong-growth-prospects--delveinsight-302397869.html